Tue, Oct 21, 2014, 9:48 AM EDT - U.S. Markets close in 6 hrs 12 mins

Recent

% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • dcaf7 dcaf7 May 21, 2014 5:46 PM Flag

    New study with Selumetinib will be started

    Official Title: A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI
    NCT02143466
    Good to see continued interest to selumetinib from AZN. It is a large 300-patient study.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Always better to be early to a party than late.

    • burnaka@sbcglobal.net burnaka May 22, 2014 4:21 PM Flag

      From the array website, not surprising Astra is looking at other indications given earlier results:

      Development Status:

      There are 45 on-going trials with selumetinib, including trials in non-small cell lung cancer, or NSCLC, thyroid cancer, melanoma, ocular melanoma, hepatocellular cancer, colorectal cancer, pancreatic cancer and breast cancer. AstraZeneca began a pivotal trial called ASTRA with selumetinib in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer in 2013. Recent presentations of significant data for selumetinib are summarized below.

      Phase 2 trial in patients with uveal melanoma – Promising data on selumetinib in an ongoing Phase 2 trial of patients with uveal melanoma were presented at the 2013 ASCO Annual Meeting. At the meeting, Memorial Sloan-Kettering Cancer Center presented data on selumetinib that showed it to be the first targeted therapy to demonstrate significant clinical benefit of more than doubling of progression-free survival for patients with metastatic uveal melanoma. These results suggest that selumetinib has the potential as a new standard of care for patients with very few treatment options. Survival for these patients with advanced disease has held steady at only nine months to a year for decades.

      Doubling overall survival, and standard of care could be great news for arry once approved.

 
ARRY
3.46-0.01(-0.43%)9:47 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.